{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Tukysa"},{"type":"CodeName","name":"ARRY-380"},{"type":"LexicalVariant","name":"ErbB-2 inhibitor ARRY-380"},{"type":"Synonym","name":"irbinitinib"},{"type":"ChemicalStructureName","name":"N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine"},{"type":"Synonym","name":"ONT-380"},{"type":"CASRegistryName","name":"937263-43-9"}],"definition":{"html":"An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.","text":"An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/tucatinib","text":"Tucatinib"},"nciConceptId":"C77896","nciConceptName":"Tucatinib","termId":594366,"name":"tucatinib","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"tucatinib"}],"links":null}